Inhaled Celecoxib shows new promise

In recent years, Cycloxygenase (COX)-2 has emerged as a therapeutic target for the prevention and treatment of various types of cancers.

However, celecoxib, a potent COX-2 inhibitor has been shown to induce heart attacks and strokes in the Phase III cancer studies which was primarily attributed to the high oral dose of celecoxib (400 mg, twice daily) employed in these studies. Inhalation drug delivery represents a novel and potential delivery route for the treatment of lung cancer.

Researchers from Florida A&M University, College of Pharmacy, demonstrated that aerosolized celecoxib at a much lower therapeutic dose than oral celecoxib shows significant inhibition of tumor progression in orthotopic NSCLC xenograft model. The study published in Pharmaceutical Research demonstrated superior efficacy of inhaled celecoxib as compared to conventional oral route of administration (Lead author: Dr. Suniket Fulzele).

Dr. Fulzele optimized the celecoxib aerosol performance and its delivery to tumor bearing mice. There are very few techniques that are available to study aerosol performance in animals. This is particularly complicated by the fact that rodents (rats/mice) have extremely small tidal volumes and unlike humans they breathe only by nose. Study of the efficacy of inhaled products in tumor bearing animals is also impaired by the differences in breathing pattern due to presence of tumors in the lungs. Dr. Fulzele and his colleagues formulated and effectively delivered celecoxib via aerosolization to treat orthotopic lung tumors in combination with intravenous docetaxel. Aerosolized celecoxib at a significantly lower therapeutic dose (4.56 mg/kg/day) demonstrated comparable anti-tumor efficacy to orally administered celecoxib (150 mg/kg/day).

The researchers demonstrated their experiments in mouse model of lung cancer. Mice treated with celecoxib (aerosol/oral) + docetaxel showed significant reduction in lung weight and tumor area as compared to celecoxib or docetaxel treatments. Combination of aerosol/oral celecoxib with docetaxel produced significant anti-tumor effect mediated via reduced prostaglandin E 2 (PGE2), IL-8 and Factor VIII levels and increased apoptosis mediated via Fas pathway.

Source - FAMU

To contact one of our specialist lawyers please call 0800 61 66 81 , or use the contact details at the top left of this page.

What our clients say about us...

"The accident that I was involved in left me helpless, alone, and fragile. Being treated like a human being instead of a number made me realise that I have an honest, competent, patient law practice handling my case. My whole experience made me feel truly cared for. You went beyond the call of duty to help me. I'm proud to be represented by one of the very best law practices in the country." Mr H Burley, Otley

select this link to see how we can help...

Questions answered online within 30 minutes

Specialised lawyer

Answered for free

No commitment

Find out more

Have I got a case?

Working with:

Law Society

Law Society Personal Injury

Association of Personal Injury Lawyers

Headway

Back Up Trust

Motor Accidents Solicitors Society

Investors in People

News centre

Latest News 05/12/08 Surgeons have carried out the first operations in Britain using a pioneering “bionic eye”... Click to read more... Scientists believe they have identified a gene that may be able to limit the growth of breast cancer... Click to read more... All News

Change Text Only Settings

Graphic version of this page